Você procurou por: platseebokontrollita (Estoniano - Inglês)

basiliksimabi kasutati koos tsüklosporiini mikroemulsiooni ja steroididega platseebokontrollita uuringus 41 de novo neerutransplantatsioonihaigel lapsel.
basiliximab was used concomitantly with ciclosporin for microemulsion and steroids in an uncontrolled study in 41 paediatric de novo renal transplant recipients.

lapsed basiliksimabi kasutati koos tsüklosporiini mikroemulsiooni ja steroididega platseebokontrollita uuringus 41 de novo neerutransplantatsioonihaigel lapsel.
paediatrics basiliximab was used concomitantly with ciclosporin for microemulsion and steroids in an uncontrolled study in 41 paediatric de novo renal transplant recipients.

4 platseebokontrolliga ja 2 platseebokontrollita kliinilises uuringus raviti eltrombopaagiga 530 kroonilise itp-ga täiskasvanud patsienti.
in 4 controlled and 2 uncontrolled clinical studies, 530 chronic adult itp patients were treated with eltrombopag.

bosentaani õhukese polümeerikattega tablettide efektiivsust hinnati avatud platseebokontrollita uuringus, kus osales 19 pulmonaalse arteriaalse hüpertensiooniga pediaatrilist patsienti vanuses 3 kuni 15 aastat.
bosentan film-coated tablets were evaluated in an open-label uncontrolled study in 19 paediatric patients with pulmonary arterial hypertension aged 3 to 15 years.

nendel patsientidel teostatud platseebokontrollita uuringute andmed, kus lamivudiini manustati enne maksatransplantatsiooni ja selle ajal, on näidanud efektiivset hbv dna supressiooni ja alt normaliseerumist.
21 in non-controlled studies, where lamivudine was administered prior to and during transplantation, effective hbv dna suppression and alt normalisation was demonstrated.

allpool on toodud ka pikemaajalistest platseebokontrollita uuringutest (aries-e ja ambition (kombinatsioon tadalafiiliga)) saadud andmed.
information from longer term non-placebo controlled studies (aries-e and ambition (combination with tadalafil)) is also included below.

ac-052-356 oli avatud platseebokontrollita uuring; 12-nädalase uuringu ajal sai 10 pediaatrilist patsienti 19-st bosentaaniga samaaegselt ka epoprostenoolravi.
ac-052-356 was an open- label, uncontrolled study; 10 of the 19 paediatric patients were on concomitant bosentan and epoprostenol therapy during the 12-week study.

kolmes platseebokontrollitud ja kahes platseebokontrollita kliinilises uuringus tekkis eltrombopaagi saanud kroonilise itp-ga täiskasvanute seas (n = 446) 17 uuritaval kokku 19 trombemboolilist tüsistust, milleks olid (esinemissageduse vähenemise järjekorras) süvaveenitromboos (n = 6), kopsuemboolia (n = 6), äge müokardiinfarkt (n = 2), ajuinfarkt (n = 2), emboolia (n = 1) (vt lõik 4.4).
in 3 controlled and 2 uncontrolled clinical studies, among adult chronic itp patients receiving eltrombopag (n=446), 17 subjects experienced a total of 19 tees, which included (in descending order of occurrence) deep vein thrombosis (n=6), pulmonary embolism (n=6), acute myocardial infarction (n=2), cerebral infarction (n=2), embolism (n=1) (see section 4.4).